Acadia Pharmaceuticals reported 0 in Interest Expense on Debt for its fiscal quarter ending in September of 2024.


Interest Expense On Debt Change Date
Acadia Pharmaceuticals 0 4.12M Sep/2024
ALKERMES USD 0 0 Jun/2025
Alnylam Pharmaceuticals USD 40.25M 1.6M Jun/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 2.68M 184K Jun/2025
Bristol-Myers Squibb USD 485M 9M Jun/2025
Corcept Therapeutics 6M 6M Jun/2024
Cytokinetics USD 24.26M 1.32M Jun/2025
Eisai 916M 174M Jun/2025
Eli Lilly USD 249M 5.3M Jun/2025
Incyte USD 594K 66K Jun/2025
J&J USD 128M 9M Mar/2025
Moderna USD 1000K 0 Jun/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Pfizer USD 654M 0 Jun/2025
Prothena 0 0 Jun/2024
PTC Therapeutics USD 30.36M 4.03M Jun/2025
Sarepta Therapeutics USD 5.23M 725K Jun/2025
Ultragenyx Pharmaceutical 14.04M 1.48M Jun/2025
Vertex Pharmaceuticals USD 3.7M 900K Jun/2025